Significance, aetiology and prevention of venous thromboembolism in pregnancy and puerperium;Značaj, etiologija i prevencija venskog tromboembolizma u trudnoći i puerperijumu

Vojnosanitetski Pregled

Volumn 71, Issue 6, 2014, Pages 580-587

  Kutlešić, Marija ^a   Kutlešić, Ranko ^a   Koracević, Goran ^a  

^a Clinical Center Ni   (Serbia)

Author keywords

Heparin; Low molecular weight; Postpartum period; Pregnancy; Risk factors; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; DALTEPARIN; DANAPAROID; DEXTRAN; ENOXAPARINE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN; FIBRINOLYTIC AGENT;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; FETAL HEMORRHAGE; GENE MUTATION; HORMONAL REGULATION; HUMAN; INFERTILITY THERAPY; LOW DRUG DOSE; LOWER ABDOMINAL PAIN; PREGNANCY; PUERPERIUM; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; ADULT; COMPLICATION; FEMALE; HIGH RISK PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PUERPERAL DISORDERS; RECURRENT DISEASE; YOUNG ADULT;

ADULT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY, HIGH-RISK; PUERPERAL DISORDERS; RECURRENCE; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84903307604     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1406580K     Document Type: Article

References (83)

1. Middeldorp S. How i treat pregnancy-related venous thromboembolism. Blood 2011; 118(20): 5394-5400.
2. Fiengo L, Bucci F, Patrizi G, Giannoti D, Redler A. Postpartm deep vein thrombosis and pulmonary embolism in term pregnancy: understanding of clinical symptoms leading to massive complications. Thromb J 2013; 11(1): 4.
3. James AH, Konkle BA, Bauer KA. Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. Int J Womens Health 2013; 5: 233-241.
4. McLintock C, Brighton T, Chunilal S, Dekker G, McDonnell N, McRae S, et al. Recommendations for the prevention of pregnancy-associated venous thromboembolism. Aust N Z J Ob-stet Gynaecol 2012; 52(1): 3-13.
5. Sultan AA, Tata LJ, West J, Fiaschi L, Fleming KM, Nelson-Piercy C, et al. Risk factors for first venous thromboembolism in and around pregnancy; a population-based cohort study from the United Kingdom. Blood 2013; 121(19): 3953-3961.
6. Bagaria SJ, Bagaria VB. Strategies for diagnosis and prevention of venous thromboembolism during pregnancy. J Pregnancy 2011; 2011: 206858.
7. Arya R. How I manage venous thromboembolism in pregnancy. Br J Hematol 2011; 153(6): 698-708.
8. Weitz JI. Prevention and treatment of venous thromboembolism during pregnancy. Catheter Cardio Intery 2009; 74(S1): S22-S26.
9. James AH. Venous thromboembolism in pregnancy. Arterio-scler Thromb Vasc Biol 2009; 29(3): 326-331.
10. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003; 70(1): 7-30.
11. McLeod AG, Ellis C. Prevention and treatment of venous thromboembolism in high risk situations in pregnancy. Fetal Maternal Med Rev 2005; 16(1): 51-70.
12. Schafer AI, Levine MI, Konkle BA. Thrombotic disorders: diagnosis and treatment. Hematology Am Soc Hematol Educ Program 2003: 520-539.
13. Greer IA. Prevention of venous thromboembolism in pregnancy. Best Practice Res Clin Haematol 2003; 16(2): 261-78.
14. Schreiber D. Deep venous thrombosis and thrombophlebitis. Emergency medicine [homepage on the Internet]. Available from: http://www.emedicine.medscape.com/. [updated 2010 Jun 10; cited 2010 Dec 11].
15. Martin SR, Foley MR. Intensive care in obstetrics: an evidence-based review. Am J Obstet Gynecol. 2006; 195(3): 673-689.
16. James A. Committee on Practice Bulletins-Obstetrics. Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 2011; 118(3): 718-729.
17. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, et al. Diagnosis of DVT.Antithrombotic therapy and prevention of thrombosis. 9th ed. Amedican College of Chest Physicians. Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2 Suppl): e381S-e418S.
18. McLintock C. Venous thromboembolism and pregnancy. O&G Magazine 2013; 15(1): 39-40
19. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and aditional risk factors from a London perinatal data base. RCOG 2001. BJOG 2001; 108(1): 56-60.
20. Bates SM. Management of pregnant women with thrombophilia or a history of venous thromboembolism. Hematology Am Soc Hematol Educ Program 2007: 143-150.
21. Previtali E, Bucciarelli P, Pessamonti SM, Martinelli I. Risk factors for venous and artherial thrombosis. Blood Transfus 2011; 9(2): 120-138.
22. Suneja A, Rashmi, Arora M, Agarwal N. Deep vein thrombosis in pregnancy. J Ind Acad Clin Med 2001; 2(4): 260-269.
23. Chan WS, Spenser FA, Ginsbergm JS. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ 2010; 182(7): 657-660.
24. Kaaja R. Is deep vein thrombosis different during pregnancy? (Commentary). CMAJ 2010; 182(7): 649-650.
25. Kupferminc MJ, Eldor A, Steinman N, Many A, BarAm A, Jaffa A, et al. Increased frequency of genetic thrombophillia in women with complications of pregnancy. N Engl J Med 1999; 34(5): 384-389.
26. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy and pregnancy. Antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidene-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e691S-e736S.
27. Dresang LT, Fontaine P, Leeman L, King VJ. Venous thromboembolism during pregnancy. Am Fam Physician 2008; 77(12): 1709-1716.
28. Maclean PS, Tait C. Hereditary and acquired antithrombin deficiency; epidemiology, pathogenesis and treatment options. Drugs 2007; 67(10): 1429-1440.
29. Dawood F. Pregnancy and thrombophilia. J Blood Disorders Transf; 4: 164.
30. Lockwood CJ. Inherited thrombophilias in pregnant patients: detecdion and treatment paradigm. Obstet Gynecol 2002; 99(2): 333-341.
31. Djordjevic V, Pruner I, Radojkovic D. Molecular basis of thrombophilia. J Med Biochem 2014; 33: 22-27.
32. Ivanov P, Tomov S, Tsvyatkovska T, Konova E, Komsa-Penkova R Thrombophilia in assisted reproductive technology - place and needs for thromboprophylaxis. In: Ivanov P, editor. Pregnancy thrombophilia - the unsuspected risk. Rijeka, Croatia: InTech; 2013. p. 129.
33. Al-Hamodi ZH, SaifAli R, Ismail IS, Ahmed KA, Muniandy S. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolis syndrome parameters in Malaysian subjects. J Clin Boichem Nutr 2012; 50(3): 184-189.
34. Lane D, Grant P. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95(5): 1517-1532.
35. Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 2007; 97(6): 907-913.
36. Sartori MT, Danesin C, Saggiorato G, Tormene D, Simioni P, Spiezia L et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost 2003; 9(4): 299-307.
37. Singh NK, Gupta A, Dibyi R, Dash D. Elevated plasminogen activator inhibitor type - 1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome. Rheumatol Int 2013; 33(9): 2331-2336.
38. Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, El-dor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 2001; 97(1): 44-48.
39. Tempfer CB, Riener EK, Hefler LA, Keck C. Genetic thrombophilia has pleiotropic effects in pregnancy. Personalized Med 2004; 1(1): 105-114.
40. Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood 2004; 103(11): 4003-4009.
41. De Stefano V, Martinelli I, Rossi E, Battagiloli T, Za T, Mannuccio P, et al. The risc of reccurent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006; 135(3): 386-391.
42. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132(2): 171-196.
43. Bates SM. Preventing thrombophilia-related complications of pregnancy: an update. Expert Rev Hematol 2013; 6(3): 287-300.
44. Barini R, Annichino-Bizzache J, Couto E, Nomura ML, Soligo AG, Machado IN. Main Types of Clinical Appearance of Thrombo-philic States During Pregnancy - Target Groups for Throm-bophilia Testing. In: Ivanov P, editor. Pregnancy thrombophilia - the unsuspected risk. Rijeka, Croatia: InTech; 2013. p. 39.
45. Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top Guideline No 37. London: Royal College of Obstetricians and Gynaecologists; 2009.
46. Brill-Edvards P, Ginsberg JS, Gent M, Hirsch J, Burrows R, Kearon C, et al. Safety of witholding heparin in pregnant women with a history of venous thromboembolism Recurrence of clot in this pregnancy study group. N Eng J Med 2000; 343(20): 1439-1444.
47. Roeters VanLennep JE, Meijer E, Klumper FJ, Middeldop JM, Bloe-menkamp KW, Middeldorp S. Prophylaxis with low-dose low molecular weight heparin during pregnancy and puerperium: is it effective? J Thromb Haemost 2011; 9(3): 473-480.
48. Stratta P, Canavese C, Cena T, Quaglia M, Pergolini P, Bellomo G, et al. Low molecular weight heparin and pregnancy, when the dose does it: a nephrologists s opinion:a rebuttal. J Thromb Haemost 2011; 9(10): 2127-2129.
49. Phabinger I, Grafenhofer H, Kaider A, Kyrle A, Quehenberger P, Mannhalters C, et al. Risk of pregnancy-associated reccurent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3(5): 949-954.
50. Salmon JE, deGroot PG. Pathogenic role of antiphospholipid antibodies. Lupus 2008; 17(5): 405-411.
51. Feinberg BB. Preeclampsia: the death of Goliath. Am J Reprod Immunol 2006; 55(2): 84-98.
52. Mello G, Parreti E, Marozio L, Pizzi C, Lojacono A, Frusca T, et al. Thrombophilia is significatly associated with severe preeclampsia. Hypertension 2005; 46: 1270-1274.
53. Phabinger I, Grafenhofer H, Kaider A, Ilic A, Eichinger S, Quechen-berger P, et al. Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 2001; 21(5): 874-879.
54. Omar SZ, Qvist R, Khaing SL, Muniandy S, Bhalla S. Thrombo-philic mutations in preeclampsia and pregnancy induced hypertension. J Obstet Gynaecol Res 2008; 34(2): 174-178.
55. Alguel G, Vormittag R, Simanek R, Kyrle PA, Quehenberger P, Mannhalter C, et al. Preeclampsia and pregnancy loss in women with a history of venous thromboembolism and prophylactic low molecular weight heparin during pregnancy. Thromb Haemost 2006; 96(3): 285-289.
56. Mello G, Paretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al. Low molecular weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin converting enzyme DD women. Hypertension 2005; 45(1): 86-91.
57. Morgan ES, Wilson E, Watkins T, Gao F, Hunt BJ. Maternal obesity and venous thromboembolism. Int J Obstet Anesth 2012; 21(3): 253-263.
58. Jakobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6(6): 905-912.
59. Adriance SM, Muphy CV.Prophylaxis and treatment of venous thromboembolism in the critically ill. Int J Crit Illn Inj Sci 2013; 3(2): 143-51.
60. Koracevic G, Pavlovic M, Andrejevic S, Burazor M, Todorovic L, Sta-nojkovic Z. New recommendation for heparin use in acute coronary syndromes critical review. Acta Medica Medianae 2000; 39(3): 53-59. (Serbian)
61. Koracevic G Six almost unknown reasons why LMWH is better than unfractionated heparin in therapy of patients with present or threating heart failure. In: Braissant O, Wakamatsu H, editors. Recent Research in Modern Medicine 2011: Proceedings of the 2nd International Conference of the World Scientific and Engineering Academy and Society; 2011 Feb 23 - 25; Cambridge UK: WSEAS Press; 2011. p. 137-141.
62. Koracević G, Andrejević S, Sakać D, Stanojević Z, Stefanović S, Antović J, et al. Heparin rebound phenomenon in acute coronary syndromes: advantage of low molecular weight heparins. Facta Univ Ser Med Biol 2000; 7(1): 62-9.
63. Koracevic G LMWHs have an additional advantage over unfractioned heparin: no volume load. Swiss Med Wkly 2009; 139 (43-44): 642.
64. Alquwairani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A review of the pharmacology, dosing and complications. Cuurr Emerg Hosp Med Rep 2013; 1(2): 83-97.
65. Rawat A, Huynh TT, Peden EK, Kougias P, Lin PH. Primary prophylaxis of venous thromboembolism in surgical patients. Vasc Endovascr Surg 2008; 42(3): 205-216.
66. Chakrabarti R, Das SK Advances in antithrombotic agents. Cardiovasc Hematol Agents Med Chem 2007; 5(3): 175-185.
67. Gutt CN, Oniu T, Wolkener F, Mehrabi A, Mistry S, Buchler MW. Prophylaxis and treatment of deep vein thrombosis in general surgery. Am J Surg 2005; 189(1): 14-22.
68. Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 133(1): 19-34.
69. Daneschvar HL, Daw H. Heparin- induced thrombocytopenia (an overview). Int J Clin Pract 2007; 61(1): 130-137.
70. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 133(3): 259-269.
71. Ekbatani A, Azaro LR, Malinow AM. Anticoagulation with agratoban in a patient with heparin-indced thrombocytopenia. Int J Obstet Anesth 2010; 19(1): 82-87.
72. Knol HM, Schultinge L, Erwich M, Meijer K Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost 2010; 8(8): 1876-1879.
73. Koracevic G What is heparin rebound? Exploring the parallel meanings that have existed for over 45 years. Cardiol Rew (USA) 2008; 25(5): 17-20.
74. Koracevic G 'Heparin rebound' means the opposite in cardiac surgery (bleeding) and in cardiology (thrombosis). Blood Co-agul Fibrinolysis 2010; 21(2): 198-199.
75. Hammerstingl C. Monitoring therapeutic anticoagulation with low molecular weight heparins: is it useful or misleading? Cardiovasc Hematol Agent Med Chem 2008; 6(4): 282-286.
76. Lambert JR, Austin SK, Peebles D, Cohen H. Audit of the peri-delivery use of unfractionated heparin in women on therapeutic low-molecular weight heparin. Br Haematol 2008; 142(3): 453-456.
77. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SI, Benzon HT, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy; American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (Thrd Ed). Reg Anesth Pain Med 2010; 35(1): 64-101.
78. Roshani S, Cohn DM, Stehouwer AC, Wolf H, van der Post JA, Bul-ler HR, et al. Incidence of postpartum haemorrhage in women receiving therapeutic doses of low-molecular-weight heparin: result of a retrospective cohort study. BMJ Open 2011; 1(2): e000257.
79. Butwick AJ, Carvalho B. Neuraxial anesthesia in obstetrics patients receiving anticoagulant and antithrombotic drugs. Int J Obstet Anesth 2010; 19(2):193-201.
80. Nicolaides AN, Fared J, Kakkar AK, Breddin HK, Goldhaber SZ, Hull R, et al. Prevention and treatment of venous thromboembolism. International consensus statement (Guidelines according to scientific evidence). Int Angiol 2006; 25(2): 101-161.
81. Stratta P, Canavese C, Cena T, Quaglia M, Pergolini P, Bellomo G, Maget al. Low molecular weight heparin and pregnancy, when the dose does it: a nephrologists s opinion: a rebuttal. J Thromb Haemost 2011; 9(10): 2127-2129.
82. Jamieson R, Calderwood CJ, Greer IA. The effect of graduated compression stockins on blood velocity in the deep venous system of the lower limb in the postnatal period. BJOG 2007; 114(10): 1292-1294.
83. Lindquist PG, Hellgren M. Is obstetric thromboprophylaxis with low-molecular weight heparin effective? Yes, if administred properly. J Thromb Haemost 2011; 9(8): 1669-1670.